This SPORE recognizes that a sustained, dynamic and cutting-edge program to improve patient outcomes is dependent upon attracting the most promising young scientists to study cervical cancer and nurturing their careers. We further recognize the importance of seeking out such talent among minorities and women, and helping these faculty members overcome barriers to flourish as independent scientists with thoughtful mentorship and practical help. The Career Development Program of the Cervical Cancer SPORE continues to attract and stimulate young investigators to carry out translational research related to cervical cancer and provide mentorship. Candidates submit an application and are evaluated through a careful selection process involving a career development committee headed by Dr. T.-C. Wu, the SPORE PI as well as the SPORE steering committee. Dr. Partridge, the Clinical Research Director for SPORE from University of Alabama at Birmingham (UAB) assists in the translational and clinical efforts of awarded investigators. Recipients of the award are reviewed annually and investigators are required to submit an annual progress report subject to the aforementioned review process. In addition, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (JHU) also provides $75,000 annually as match funds for the Career Development Program. UAB will also contribute $40,000 annually to be used in the Career Development or Developmental Research Programs. This continues to be an impactful program that has recruited and developed a cadre of outstanding translational scientists, including several new leaders in this Cervical Cancer SPORE, and incorporated their innovations and expertise into this program. We are excited about our new collaboration with Mount Sinai School of Medicine, and reaching out to their young faculty. Specific Goals To attract, select and mentor promising young scientists with a special emphasis on recruiting qualified women and minorities. To develop and support the awardee?s rigorous and innovative translational research program addressing cervical cancer

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA098252-11
Application #
8747966
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
2003-09-30
Project End
2019-08-31
Budget Start
2014-09-24
Budget End
2015-08-31
Support Year
11
Fiscal Year
2014
Total Cost
$156,990
Indirect Cost
$49,360
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Yang, Andrew; Farmer, Emily; Lin, John et al. (2016) The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res :
Yang, Andrew; Farmer, Emily; Wu, T C et al. (2016) Perspectives for therapeutic HPV vaccine development. J Biomed Sci 23:75
Khan, Michelle J; Massad, L Stewart; Kinney, Walter et al. (2016) A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. Gynecol Oncol 141:364-70
Khan, Michelle J; Massad, L Stewart; Kinney, Walter et al. (2016) A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results. J Low Genit Tract Dis 20:119-25
Jiang, Rosie T; Schellenbacher, Christina; Chackerian, Bryce et al. (2016) Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines 15:853-62
Wang, Yi-Shu; Chen, Jianfeng; Cui, Fengmei et al. (2016) LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors. Oncotarget :
Sun, Yun-Yan; Peng, Shiwen; Han, Liping et al. (2016) Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract. Clin Cancer Res 22:657-69
Jones, Jacqueline; Mukherjee, Angana; Karanam, Balasubramanyam et al. (2016) African Americans with pancreatic ductal adenocarcinoma exhibit gender differences in Kaiso expression. Cancer Lett 380:513-22
Randles, Leah; Anchoori, Ravi K; Roden, Richard B S et al. (2016) The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression. J Biol Chem 291:8773-83
Yang, Andrew; Jeang, Jessica; Cheng, Kevin et al. (2016) Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines 15:989-1007

Showing the most recent 10 out of 251 publications